Novel Antibody for the Treatment of Transthyretin Amyloidosis

J Biol Chem. 2016 Nov 25;291(48):25096-25105. doi: 10.1074/jbc.M116.738138. Epub 2016 Oct 7.

Abstract

Familial amyloidotic polyneuropathy (FAP) is a systemic amyloidosis mainly caused by amyloidogenic transthyretin (ATTR). This incurable disease causes death ∼10 years after onset. Although it has been widely accepted that conformational change of the monomeric form of transthyretin (TTR) is very important for amyloid formation and deposition in the organs, no effective therapy targeting this step is available. In this study, we generated a mouse monoclonal antibody, T24, that recognized the cryptic epitope of conformationally changed TTR. T24 inhibited TTR accumulation in FAP model rats, which expressed human ATTR V30M in various tissues and exhibited non-fibrillar deposits of ATTR in the gastrointestinal tracts. Additionally, humanized T24 (RT24) inhibited TTR fibrillation and promoted macrophage phagocytosis of aggregated TTR. This antibody did not recognize normal serum TTR functioning properly in the blood. These results demonstrate that RT24 would be an effective novel therapeutic antibody for FAP.

Keywords: FAP; amyloid; antibody; antibody engineering; drug design; fibril; transthyretin.

MeSH terms

  • Amyloid Neuropathies, Familial / drug therapy*
  • Amyloid Neuropathies, Familial / immunology*
  • Amyloid Neuropathies, Familial / pathology
  • Animals
  • Antibodies, Monoclonal, Murine-Derived / immunology*
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Female
  • Humans
  • Macrophages / immunology*
  • Macrophages / pathology
  • Male
  • Mice
  • Phagocytosis / drug effects*
  • Prealbumin / immunology*
  • Rats

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Prealbumin

Supplementary concepts

  • Amyloidosis, Hereditary, Transthyretin-Related